Latest News and Press Releases

Reiterate topline data from Phase 2 Cystic Fibrosis clinical trials for ELX-02 expected in H1 2020 Results from clinical and preclinical research to date support Company’s prioritization of Cystic...

Phase 2 cystic fibrosis program for ELX-02 expected to be fully enrolled in the first quarter of 2020 and topline results expected during the first half of 2020 Positive Phase 2 topline data reported...

WALTHAM, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...

WALTHAM, Mass., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...

WALTHAM, Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...

WALTHAM, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...

-Presented Positive Phase 1 Data from SAD and MAD Studies at North American Cystic Fibrosis Conference -On track to report top line Phase 2 data in nephropathic cystinosis this quarter, preliminary...

Eloxx presented findings from the Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) studies and additional preclinical data for ELX-02 Eloxx will provide an update on the Phase 2...

WALTHAM, Mass., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...

CF Foundation and Eloxx to form joint program advisory group focused on the development of ELX-02 for cystic fibrosis Eloxx plans to conduct the U.S. portion of the Phase 2 clinical trial at Cystic...